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Abstract Cardiovascular allografts are usually dis-
infected using antibiotics, but protocols vary signifi-
cantly between tissue banks. It is likely that different
disinfection protocols will not have the same level of
efficacy; they may also have varying effects on the
structural integrity of the tissue, which could lead to
significant differences in terms of clinical outcome in
recipients. Ideally, a disinfection protocol should
achieve the greatest bioburden reduction with the
lowest possible impact on tissue integrity. We con-
ducted a systematic review of methods applied to
disinfect cardiovascular tissues. The use of multiple
broad spectrum antibiotics in conjunction with an
antifungal agent resulted in the greatest reduction in
bioburden. Antibiotic incubation periods were limited
to less than 24 h, and most protocols incubated tissues
at 4 C, however one study demonstrated a greater
reduction of microbial load at 37 C. None of the
reviewed studies looked at the impact of these
disinfection protocols on the risk of infection or any
other clinical outcome in recipients.
Keywords Cardiovascular allografts  Tissue
donation  Tissue decontamination  Bioburden 
Tissue banking
Introduction
Prior to the advent of tissuepreservation, transplantation
of cardiac valves had to occur shortly after recovery to
reduce the incidence of contamination and tissue
damage. Advances in cardiovascular preservation have
allowed for the creation of heart valve banks worldwide
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to increase the number and quality of heart valves
available for transplantation (Chaukar et al. 1990; Gall
et al. 1998;Germain et al. 2010;Goffin et al. 1996;Heng
et al. 2013a, b; Jashari et al. 2007; Tabaku et al. 2004;
Verghese et al. 2004; Villalba et al. 2009). However,
additional processing steps have increased the preva-
lence of contamination in these tissues. The presence of
microorganisms can pose a serious and sometimes lethal
threat to the transplant recipient (CDC,C. forD.C. andP
1997; Kuehnert et al. 1998). Heart valve banks have
employed a variety of procedures to both determine and
reduce bioburden, which has improved the quality of
stored grafts, as well as the outcomes for the transplant
recipient (Tabaku et al. 2004).
The contamination rate represents the proportion of
tissues with bacterial or fungal contamination, and the
bioburden denotes the quantity of organisms on each
sample. As it relates to cardiac grafts, bioburden
reduction (disinfection) is defined as a process applied
following recovery, which reduces or eliminates bacte-
ria or fungal contamination (Kairiyama et al. 2009).
Reduction due to antimicrobial intervention can be
assessed qualitatively in relation to changes in contam-
ination rate or quantitatively by determining the
bioburden load before and after an intervention.
Secondary outcomes, following disinfection, will allow
the assessment of the effects of bioburden reduction
processes on tissue viability and structural integrity.
Methods
Information sources and search
The search strategy was developed and reviewed by
the Cardiac Processing and Validation Subgroup
(through JM) and assisted by an information specialist.
The search was applied to electronic databases MED-
LINE and EMBASE from 1988 to July 2, 2014 using
the following headings and text words: ‘‘heart valve,’’
‘‘cardiac valve,’’ ‘‘aortic valve,’’ ‘‘pulmonary valve,’’
‘‘allograft,’’ ‘‘anti-bacterial,’’ ‘‘anti-fungal,’’ ‘‘steril-
ization,’’ and ‘‘tissue banking.’’ The search included
publications in English and excluded animal studies,
case reports and conference abstracts. Two additional
reviewers (AG and AD) performed a second search to
include publications from July 2014 up to March 6,
2015. The detailed search strategy is shown in Online
Resource 1.
Study selection
Three reviewers (CP, JM, and SF) independently
screened each of the citations in duplicate to identify
studies that included an evaluation of disinfection of
human cardiac valves or cardiac conduits, and/or
included bioburden as an outcome. If during the
screening process there were disagreements, the full
report was retrieved and the independent assessment
was repeated. Disagreements for inclusion were
resolved by consensus.
Data abstraction
The design of data abstraction forms and evidence
tables were guided by the questions in the analytic
framework (Online Resource 2) and approved and
finalized by the Cardiac Processing and Validation
Subgroup (through JM). Two reviewers (AG and AD)
independently collected the data, and a third reviewer
(NS) confirmed the data abstraction for the following
study characteristics: first author, year of publication,
location of study, sample size, donor types, recovery
site, tissue types, pre-recovery skin preparation, stor-
age and incubation parameters, and preservation
methods. Microbial testing methods were documented
for each study. Abstracted outcome data included:
bioburden immediately following recovery, antimi-
crobial intervention following bioburden assessment,
incubation parameters, proportion of allografts dis-
carded due to contamination, and logarithmic reduc-
tion of bioburden load.
Quality assessment
There were no clinical studies found among the final
pool of included articles and therefore no studies that
could be qualified by the GRADE assessment. There is
no validated quality assessment tool for laboratory-
based studies, such as GRADE, because basic science
research is inherently considered level IV, or low
quality evidence (Guyatt et al. 2011).
Data analysis
Data abstracted from all of the included studies were
organized into tables demonstrating study character-
istics, microbial testing methods, and outcomes.
Descriptive statistics included the bioburden outcome,
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the proportion of discarded allografts and the loga-
rithmic reduction of bioburden. Proportions, means,
ranges, and measures of variance such as standard
deviations (SD) are presented when available. Where
appropriate, data analysis was performed separately
for the report by Heng et al. (2013a), as this study
monitored bioburden reduction among 24 different
sites internationally (Heng et al. 2013a).
Results
Study selection
A total of 4353 citations were reviewed after dupli-
cates were removed and three additional citations were
identified by a separate search of references (Fig. 1).
Of the 4356 citations, 4325 were excluded because
they did not fulfill the screening criteria. The full text-
articles of the remaining 31 citations were retrieved for
further evaluation. Twenty-one laboratory based stud-
ies that reported a disinfection method and bioburden
as an outcome were included. Nine studies were
excluded for varying reasons listed in Online Resource
3. Following the updated search, an additional 78
articles were reviewed, and one was identified for
further evaluation. The article was included in this
review.
Study characteristics and culture methods
All included studies were conducted from 1990 to
2013. Six of the 22 laboratory investigations (Table 1)
were conducted in Belgium; two each from Australia,
India, Singapore, and Spain; and one each from
Bangladesh, Brazil, Canada, Ireland, Netherlands,
South Africa, and the USA. One additional study
was conducted at 24 different sites worldwide (Heng
et al. 2013a). Six studies indicated that the recovery of
tissues from organ donors was performed in operating
theatres of a hospital setting. Five studies recovered
cadaveric tissues in the autopsy room. Thirteen studies
did not specify where recovery took place (Online
Resource 4).
Following recovery of the cardiac tissue, 7 studies
stored the samples in cold saline, and 4 stored the
samples in tissue culture medium. The remaining 11
tissue banks did not report their storage solutions. In
10 studies, the reported method of long-term storage of
cardiac tissue was through cryopreservation, which is
storage in the vapour phase of liquid nitrogen in a
cryopreservation medium containing 10 % dimethyl-
sulfoxide (DMSO). Most studies did not report a
method for allograft preservation.
The culture methods used to determine bioburden
are outlined in Online Resource 5. All studies assessed
for the presence of bacteria and fungi in the tissue
samples by culturing of a sample of the tissue, and
testing for the presence of bacterial or fungal growth.
Five studies also included serological analysis for the
presence of viruses.
Study outcomes
Microbe identification and bioburden analysis
Microbial sampling was conducted in a total of 33,300
cardiac valves (including arteries) from 7641 donors
in 21 studies. Bioburden analysis determined that the
most commonly found contaminating bacteria
included Staphylococci, Propionobacterium, Strepto-
cocci, and Escherichia coli. In the reports that cultured
for fungi, the most predominant fungi were Candida
species. The contamination rate following recovery of
the allografts ranged from 8 to 100 % of the total
number of tissue samples isolated (Mean: 31.0 %, SD:
22.7 %) (Online Resource 6). Cryopreservation was
utilized for long-term storage of allografts in 14
studies and at all 24 sites in the multinational study.
The remaining 9 studies did not indicate a preservation
method.
Bioburden reduction
Given the relatively high contamination rate following
recovery of cardiac tissue, the need to reduce
contamination is of utmost importance. In all studies,
an antimicrobial-intervention was chosen to reduce
contamination. Every study used a combination of
broad-spectrum antibiotics, which included but were
not limited to, penicillin, streptomycin, cefoxitin,
vancomycin, amikacin and gentamicin. The most
commonly used antibiotic was vancomycin (77 % of
studies). Only 11 of the 22 studies reported the
inclusion of an anti-fungal agent (nystatin, polymyxin
B or amphotericin B) to reduce fungal bioburden. The
greatest reduction in contamination rate was seen in
two studies. Villalba et al. (2009) added an antibiotic
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cocktail composed of amikacin (50 lg/ml), van-
comycin (50 lg/ml), metronidazole (50 lg/ml), and
amphotericin B 5ug/ml and effectively reduced the
number of contaminated tissues to 3.2 %, although the
initial number of contaminated tissues was not
reported (Villalba et al. 2009). Peruzzo et al. (2006)
disinfected the tissue samples with cefoxitin (240 lg/
ml), lincomycin (120 lg/ml), polymyxin B (100 lg/
ml), and vancomycin (50 lg/ml), and were able to
reduce the proportion of allografts discarded from 8 to
5.6 % (Peruzzo et al. 2006). Both reports included a
combination of broad-spectrum antibiotics as well as
an anti-fungal agent. The tissues were incubated in the
antibiotic solution for 6–24 h at 4 C, or for 24 h
between 2 and 8 C. Two sites in Europe reported the
least effective reduction in contamination rate post-
processing (50 %) (Heng et al. 2013a). The reason for
failure in site 1 was bacterial contamination, whereas
reasons for failure in site 2 included abnormal
morphology, bacterial contamination and other tech-
nical issues not related to disinfection. Site 1 incubated
at 4 C for 48 h, with the broad-spectrum antibiotic,
vancomycin, with the narrow-spectrum antibiotic,
lincomycin, and the fungicide, polymyxin B. Site 2
incubated at 2–8 C for 24 h, with broad-spectrum
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Fig. 1 Screening process flow diagram
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and the fungicides, nystatin and polymyxin B (Heng
et al. 2013a).
In the multi-site study by Heng et al. (2013a), three
heart valve banks, of the 24 sites, were able to reduce
the proportion of rejected tissues to just 10 % (Heng
et al. 2013a). At two sites in Europe, one heart valve
bank utilized a combination of vancomycin (50 lg/
mL), gentamicin (4000 lg/mL), ciprofloxacin
(200 lg/mL), and amphotericin B (50 lg/mL) at
21 C, while the other bank used fluconazole and
cefotaxime to treat heart allografts at 4 C. The third
bank with sites in Australasia or South Africa utilized
cefoxitin (240 lg/mL), lincomycin (120 lg/mL),
polymyxin B (100 lg/mL), vancomycin (50 lg/mL),
and amphotericin B (25 lg/mL) at 4 C.While the use
of multiple broad spectrum antibiotics with an anti-
fungal agent was effective in the first European site as
well as the Australasian/South African site, the second
European bank was able to achieve the same result
using only one broad-spectrum antibiotic (cefoxitin)
and one anti-fungal agent (fluconazole).
Four studies utilized an incubation temperature of
37 C instead of 4 C, and had a reduced incubation
time between 6 and 12 h (Gall et al. 1995; Heng et al.
2013b; Ireland and Spelman 2005; van Kats et al.
2010). This resulted in an average reduction of
contamination to only 8.1 %, compared to 5.9 % for
tissues incubated at 4 C for an extended period. In the
survey by Heng et al. (2013a), there was no difference
in the contamination reduction rate between the
6–12 h incubation at 37 C and 24–48 h incubation
at 37 C (29.8 and 30.2 %, respectively). In Germain
et al. (2010), incubation of tissues at 37 C with
antibiotics was more effective in bioburden reduction
at higher temperatures. At 37 C, the authors were
able to disinfect the tissues completely, reducing the
bioburden from 5000 to 0 CFU/ml (3.7 fold logarith-
mic reduction in the bioburden). Conversely, incuba-
tion of tissues at 4 C with antibiotics were only able
to reduce the bioburden from 5000 to 3.6 CFU/ml (a
3.1 fold logarithmic reduction in bioburden) (Germain
et al. 2010).
Confounding factors
The use of antibiotics to disinfect the allografts was
common among all reports, but the parameters for the
antibiotic treatment were highly varied. The time
period for which the samples were incubated in the
disinfection solution varied from 12 h up to 6 weeks.
By extending the incubation period, the authors
allowed for elimination of more microorganisms, but
viability of the tissues was not assessed following
these extended incubation periods. Additionally, four
studies reported incubation of the tissue at 37 C
rather than 4 C as in most other studies (Chaukar
et al. 1990; Germain et al. 2010; Heng et al. 2013b; van
Kats et al. 2010). At one of the 24 sites in Heng et al.
(2013a), the tissue bank modified their incubation
temperature from 1–10 C to 32–38 C in the recent
past (Online Resource 6) (Heng et al. 2013a). The
majority of antibiotics are more effective at higher
temperatures, but the integrity of the allografts may be
compromised at this temperature for extended periods
(Goffin et al. 1996).
Discussion
Following recovery of the heart allograft, the usage of
broad and narrow spectrum antibiotics coupled with
an antifungal agent at 4 C for up to 2 days had the
greatest reduction in the proportion of allografts
contaminated with a microorganism (Villalba et al.
2009). The proportion of cardiac allografts requiring
disinfection following recovery was quite high.
Cleaning and rinsing methods to reduce bioburden
were not reported in these studies, and recovered
allografts were often stored in Ringer’s or saline
solutions. None of the included studies reported
increased implant survival or a reduction in morbidity
and mortality following transplantation.
The initial contamination rate was found to be as
high as 100 % of all the tissues recovered (Hoque et al.
2007). A method to disinfect the skin prior to recovery
of the heart allografts was not reported in most studies.
Gall et al. (1995) reported that more allografts were
contaminated when being recovered from multi organ
donors, as opposed to cadaveric donors (14 vs. 10 %)
(Gall et al. 1995). This suggests that further precaution
might be required prior to heart valve recovery from
multi-organ donors. Although no studies had a control
group, two studies demonstrated a lower initial
contamination rate of 21.2 % when stored in saline
or Ringer’s solution (Goffin et al. 2000; van Kats et al.
2010), compared to exclusive storage of allografts in
saline in three other studies (mean contamination rate
598 Cell Tissue Bank (2016) 17:593–601
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of 46.4 %) (Fan et al. 2012; Heng et al. 2013b; Hoque
et al. 2007).
The most common microorganisms contaminating
the allografts are classified as opportunistic pathogens
(disease-causing in immunocompromised individu-
als), and positive culture of any organism warranted
disinfection of the allograft. However, in the studies in
this review, the researchers disinfected all allografts,
regardless of the level of contamination. Fungi, and
specifically the genus Candida have been identified as
significant pathogens that should preclude further
transplantation if identified in allografts (CDC, C. for
D. C. and P 1997; Kuehnert et al. 1998).
All reports sought to reduce bioburden, using
antibiotics. Antibiotics are currently the preferred
method of disinfection, as past methods of disinfection
using chemicals have been deemed too harsh, resulting
in reduced viability of heart valves (Goffin et al. 1996).
While most reports did not use the same combination
of antimicrobial agents, a lower proportion of allograft
discard was associated with studies that used a
combination of broad spectrum antibiotics, the narrow
spectrum antibiotic, lincomycin, and the antifungal
agent, polymyxin B. Heng et al. (2013a) compared the
effectiveness of a combination of penicillin and
streptomycin (two broad-spectrum antibiotics com-
monly used for disinfection of allografts) to the use of
two other broad-spectrum antibiotics (amikacin and
vancomycin). Although incubation parameters varied
for each combination, amikacin and vancomycin were
capable of reducing the allograft discard rate to 4.7 %
(1/21), as opposed to an 11.1 % (4/36) allograft
discard rate when penicillin and streptomycin were
used (Heng et al. 2013b). It should be noted that the
only contaminating organism following treatment
with amikacin and vancomycin was a fungus, which
was not targeted by these antibiotics. Jashari et al.
(2007) reported that the addition of the antifungal
agent, polymyxin B to the antibiotic cocktail reduced
the proportion of allograft discard to 4.3 %, compared
to an allograft discard rate of 5.5 %, when only the
antibiotic cocktail (lacking polymyxin B) was added
(Jashari et al. 2007). This suggests that fungal
contamination could represent a consistent, but minor
component of the contaminating bioburden.
The majority of studies reported that the cardio-
vascular allografts were incubated in an antibiotic-
containing solution for 6–24 h at 4 C. It is hypoth-
esized that lower temperatures allow for the antibiotic
to function while maintaining tissue integrity (Villalba
et al. 2009). However, in one study, incubation at
37 C showed a greater reduction in the bioburden
load compared to the same treatment at 4 C (Germain
et al. 2010). Extension of the incubation period beyond
24 h does not appear to increase the effectiveness of
the antibiotic treatment.
Limitations
Limitations in this review relate to missing or non-
reported data. Following recovery of the allografts, the
initial contamination rate was lower when the samples
were stored in saline or Ringer’s solution, compared to
storing the samples exclusively in saline. The propor-
tion of samples stored in either solution was not
reported, and thus, it is indeterminate if the Ringer’s
solution could affect the contamination rate following
recovery. Also, the addition of cleaning or rinsing
agents following recovery to reduce bioburden was not
reported in any of the studies, and therefore it remains
unclear if these procedures have a significant impact
on bioburden reduction.
Another main limitation in this review is the
heterogeneity in the experimental design among the
primary studies. Variances in initial contamination
rate, antibiotic combination and concentration, incu-
bation period, incubation temperature, and assay
method to quantify results were rarely tested within
studies. Additionally, the standards and regulations
regarding the release of contaminated tissues is not
universal among tissue banks worldwide. Regulatory
organizations like the American Association of Tissue
Banks do not allow the release of allografts contam-
inated with pathogens, but classification of pathogens
may differ among countries.
The majority of the articles presented the contam-
ination reduction rate as a proportion of allografts
discarded due to contamination or potentially rejected
due to positive culture following disinfection.
Although this was an effective qualitative metric in
terms of quality assessments of the antibiotics’
effectiveness, a more quantitative method, calculating
bioburden log reduction, would allow for more
informed recommendations for clinical implementa-
tion. Reporting of quantified values would allow for
optimization of interventions, thus improving the
quality of clinical recommendations.
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Additionally, certain outcomes, such as tissue
viability following antibiotic exposure were not
addressed in any of the 22 studies. Tissue viability is
principal to cardiovascular transplantation success,
and as such, additional studies are required to address
this issue. Finally, there was no discussion on the
acceptable levels of contamination that would allow
for allograft release. Not all organisms would neces-
sarily be pathogenic. Allografts were often discarded
based on the presence of positive cultures following
the antibiotic intervention, but identification of these
remaining organisms (such as the fungal contaminant
in Heng et al. 2013a) could elicit additional antimi-
crobial treatments that could further reduce the
proportion of allograft discard.
Conclusions
The results of this review suggest that the use of
multiple broad-spectrum antibiotics in combination
with an antifungal agent result in the greatest reduction
in bioburden. Antibiotic incubation periods were
typically no longer than 24 h, and most samples were
incubated at 4 C. One study showed a greater
reduction in microbial load in tissues at 37C6. The
majority of studies in this review did not test the
efficacies of antimicrobial interventions relative to one
another, and were all laboratory studies (level IV
evidence). The transplantation of the treated tissues
was not performed and evaluated for clinical effec-
tiveness; therefore, these outcomes should be inter-
preted with caution.
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